Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beijing Luzhu Biotechnology Co., Ltd. Class H ( (HK:2480) ) has shared an update.
Beijing Luzhu Biotechnology Co., Ltd. announced the successful completion of the Phase I clinical trial of its LZ901 vaccine in the U.S., which demonstrated good safety and immunogenicity in both high-dose and low-dose groups compared to a placebo. This milestone lays the groundwork for further clinical studies and strengthens the company’s position in the vaccine development industry, with ongoing assessments by the National Medical Products Administration of the PRC for a biologics license application.
More about Beijing Luzhu Biotechnology Co., Ltd. Class H
Beijing Luzhu Biotechnology Co., Ltd. operates in the biotechnology industry, focusing on the development of vaccines. Its core product, LZ901, is a recombinant herpes zoster vaccine aimed at preventing herpes zoster and related complications in adults aged 40 and above.
Average Trading Volume: 25,434
Technical Sentiment Signal: Buy
For a thorough assessment of 2480 stock, go to TipRanks’ Stock Analysis page.